Clinical Trial Update: CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib [Phase 3]

View source ↗

Summary

Phase 3 rollover study CATCH-R provides continued access to rucaparib for eligible patients with metastatic castration-resistant prostate cancer and ovarian can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Rucaparib (rucaparib)

Snippet

Sponsor: pharmaand GmbH | Conditions: Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-05-07